Preoperative Radiation May Improve the Outcomes of Resectable IIIA/N2 Non-small-cell Lung Cancer Patients: A Propensity Score Matching-based Analysis from Surveillance, Epidemiology, and End Results Database

Overview

Journal Cancer Med

Specialty Oncology

Date 2018 Jul 31

PMID 30058192

Citations 14

Authors

Dawei Chen

Haiyong Wang

Xinyu Song

Jinbo Yue

Jinming Yu

Affiliations

Soon will be listed here.

Abstract

Background: There are several therapeutic strategies for the management of resectable stage IIIA/N2 non-small-cell lung cancer (NSCLC) patients. However, the role of radiotherapy as a preoperative adjuvant therapy is unclear.

Methods: We retrospectively analyzed the data of stage IIIA/N2 NSCLC patients who either underwent preoperative radiation (PrORT), or did not undergo preoperative radiation, collected from the Surveillance, Epidemiology and End Results (SEER) database, between 2004 and 2013. The primary endpoints were cancer-specific survival (CSS) and overall survival (OS).

Results: Ultimately, 493 patients treated with preoperative radiation and 2675 patients treated who were not treated with preoperative radiation, were included in the analysis. Overall, preoperative radiation was associated with a better CSS (HR: 1.427 [1.297-1.572], P = 0.014) and OS (HR: 1.220 [1.131-1.493], P = 0.002) than that observed in patients who did not undergo preoperative radiation. After PSM, preoperative radiation still showed advantage in both CSS and OS. Only age, T stage, and preoperative radiation remained independent prognostic factors for both OS and CSS. In the subgroup analysis, the advantages of preoperative radiotherapy were more pronounced in patients with stage T3 tumors and highly differentiated tumors.

Conclusions: Preoperative radiation may improve the outcomes of resectable IIIA/N2 NSCLC patients. In IIIA/N2 NSCLC patients, particularly with T3 and highly differentiated tumors, clinicians should boldly apply preoperative radiotherapy to improve the patients' survival.

Citing Articles

Integrative Approaches in Non-Small Cell Lung Cancer Management: The Role of Radiotherapy.

Visa M, Abazeed M, Avella Patino D J Clin Med. 2024; 13(15).

PMID: 39124563 PMC: 11312949. DOI: 10.3390/jcm13154296.

A Systematic Review of Short-Term Outcomes of Minimally Invasive Thoracoscopic Surgery for Lung Cancer after Neoadjuvant Systemic Therapy.

Sedighim S, Frank M, Heutlinger O, Lee C, Hachey S, Keshava H Cancers (Basel). 2023; 15(15).

PMID: 37568725 PMC: 10417737. DOI: 10.3390/cancers15153908.

Patients with Lower Positive Lymph Nodes Ratio May Benefit from Preoperative Radiotherapy in Stage III Non-Small Cell Lung Cancer.

Wang R, Shang S, Huang X, Nie Y, Wang F, Yu J Technol Cancer Res Treat. 2023; 22:15330338231173498.

PMID: 37157831 PMC: 10185974. DOI: 10.1177/15330338231173498.

Lung cancer in middle and southern Morocco.

Tafenzi H, Choulli F, Baladi A, Essaadi I, Belbaraka R Ecancermedicalscience. 2023; 17:1518.

PMID: 37113715 PMC: 10129405. DOI: 10.3332/ecancer.2023.1518.

Effect of preoperative radiotherapy on overall survival in N2 non-small-cell lung cancer: a propensity score-matched analysis of Surveillance, Epidemiology, and End Results database.

Wang Y, Cao Y, Wu M, Lu Y, He B, Zhou L Interact Cardiovasc Thorac Surg. 2022; 35(1).

PMID: 35639970 PMC: 9252120. DOI: 10.1093/icvts/ivab321.

References

BROMLEY L, SZUR L . Combined radiotherapy and resection for carcinoma of the bronchus; experiences with 66 patients. Lancet. 1955; 269(6897):937-41. DOI: 10.1016/s0140-6736(55)92787-2. View

Eberhardt W, Pottgen C, Gauler T, Friedel G, Veit S, Heinrich V . Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE). J Clin Oncol. 2015; 33(35):4194-201. DOI: 10.1200/JCO.2015.62.6812. View

Shah A, Berry M, Tzao C, Gandhi M, Worni M, Pietrobon R . Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg. 2012; 93(6):1807-12. DOI: 10.1016/j.athoracsur.2012.03.018. View

Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L . 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014; 25(8):1475-84. DOI: 10.1093/annonc/mdu123. View

Warram J . Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study. Cancer. 1975; 36(3):914-25. DOI: 10.1002/1097-0142(197509)36:3<914::aid-cncr2820360312>3.0.co;2-q. View

Cox J, YESNER R, Mietlowski W, Petrovich Z . Influence of cell type on failure pattern after irradiation for locally advanced carcinoma of the lung. Cancer. 1979; 44(1):94-8. DOI: 10.1002/1097-0142(197907)44:1<94::aid-cncr2820440117>3.0.co;2-o. View

Bharadwaj S, Vallieres E, Wilshire C, Blitz M, Page B, Aye R . Higher Versus Standard Preoperative Radiation in the Trimodality Treatment of Stage IIIa Lung Cancer. Ann Thorac Surg. 2015; 100(1):207-13. DOI: 10.1016/j.athoracsur.2015.03.075. View

SHIELDS T . Preoperative radiation therapy in the treatment of bronchial carcinoma. Cancer. 1972; 30(5):1388-94. DOI: 10.1002/1097-0142(197211)30:5<1388::aid-cncr2820300537>3.0.co;2-6. View

WIDOW W . Preoperative irradiation of bronchial carcinoma. Cancer. 1971; 28(3):798-801. DOI: 10.1002/1097-0142(197109)28:3<798::aid-cncr2820280340>3.0.co;2-9. View

10.

Roth J, Atkinson E, Fossella F, Komaki R, Bernadette Ryan M, Putnam Jr J . Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998; 21(1):1-6. DOI: 10.1016/s0169-5002(98)00046-4. View

11.

Petrovich Z, Stanley K, Cox J, Paig C . Radiotherapy in the management of locally advanced lung cancer of all cell types: final report of randomized trial. Cancer. 1981; 48(6):1335-40. DOI: 10.1002/1097-0142(19810915)48:6<1335::aid-cncr2820480614>3.0.co;2-s. View

12.

Sherman D, NEPTUNE W, Weichselbaum R, ORDER S, Piro A . An aggressive approach to marginally resectable lung cancer. Cancer. 1978; 41(5):2040-5. DOI: 10.1002/1097-0142(197805)41:5<2040::aid-cncr2820410552>3.0.co;2-i. View

13.

Okamoto I, Sakai K, Morita S, Yoshioka H, Kaneda H, Takeda K . Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study. Oncotarget. 2014; 5(8):2293-304. PMC: 4039163. DOI: 10.18632/oncotarget.1906. View

14.

Perez C, Stanley K, Rubin P, Kramer S, Brady L, Perez-Tamayo R . A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer. 1980; 45(11):2744-53. DOI: 10.1002/1097-0142(19800601)45:11<2744::aid-cncr2820451108>3.0.co;2-u. View

15.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

16.

Sonett J, Suntharalingam M, Edelman M, Patel A, Gamliel Z, Doyle A . Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg. 2004; 78(4):1200-5. DOI: 10.1016/j.athoracsur.2004.04.085. View

17.

Lally B, Zelterman D, Colasanto J, Haffty B, Detterbeck F, Wilson L . Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006; 24(19):2998-3006. DOI: 10.1200/JCO.2005.04.6110. View

18.

MANFREDI F, KING R, Behnke R, HEIMBURGER I . Preoperative irradiation in bronchogenic carcinoma. Am Rev Respir Dis. 1966; 94(4):584-8. DOI: 10.1164/arrd.1966.94.4.584. View

19.

Thomas M, Rube C, Hoffknecht P, Macha H, Freitag L, Linder A . Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol. 2008; 9(7):636-48. DOI: 10.1016/S1470-2045(08)70156-6. View

20.

Kris M, Gaspar L, Chaft J, Kennedy E, Azzoli C, Ellis P . Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(25):2960-2974. DOI: 10.1200/JCO.2017.72.4401. View